載入...
Pharmacokinetic and pharmacodynamic analysis of 5-aza-2’-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy
5-Aza-2′-deoxycytidine (5-AZA-CdR, decitabine), an epigenetic drug that inhibits DNA methylation, is currently used to treat myelodysplastic syndrome (MDS), and is under investigation for treating acute myeloid leukemia (AML) and other malignancies. 5-AZA-CdR can reactivate tumor suppressor genes si...
Na minha lista:
Main Authors: | , |
---|---|
格式: | Artigo |
語言: | Inglês |
出版: |
BioMed Central
2013
|
主題: | |
在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3570332/ https://ncbi.nlm.nih.gov/pubmed/23369223 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1868-7083-5-3 |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|